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Abstract
Reduced expression of the Indy (‘I am Not Dead, Yet’) gene in lower organisms promotes 
longevity in a manner akin to caloric restriction. Deletion of the mammalian homolog of Indy 
(mIndy, Slc13a5) encoding for a plasma membrane associated citrate transporter expressed highly 
in the liver, protects mice from high-fat diet and aging-induced obesity and hepatic fat 
accumulation through a mechanism resembling caloric restriction. We aimed to study a possible 
role of mIndy in human hepatic fat metabolism. In obese, insulin resistant patients with NAFLD, 
hepatic mIndy expression was increased and mIndy expression was also independently associated 
with hepatic steatosis. In non-human primates, a two year high fat, high sucrose diet increased 
hepatic mIndy expression. Liver microarray analysis showed that high mIndy expression was 
associated with pathways involved in hepatic lipid metabolism and immunological processes. 
Interleukin-6 (IL-6) was identified as a regulator of mIndy by binding to its cognate receptor. 
Studies in human primary hepatocytes confirmed that IL-6 markedly induced mIndy transcription 
via the IL-6-receptor (IL-6R) and activation of the transcription factor Stat3 and a putative start 
site of the human mIndy promoter was determined. Activation of the IL-6-Stat3 pathway 
stimulated mIndy expression, enhanced cytoplasmic citrate influx and augmented hepatic 
lipogenesis in vivo. In contrast, deletion of mIndy completely prevented the stimulating effect of 
IL-6 on citrate uptake and reduced hepatic lipogenesis. These data show that mIndy is increased in 
liver of obese humans and non-human primates with NALFD. Moreover, our data identify mIndy 
as a target gene of IL-6 and determine novel functions of IL-6 via mINDY. Targeting human 
mINDY may have therapeutic potential in obese patients with NAFLD.
Keywords
Indy; Liver; NAFLD; Insulin Resistance; IL-6
Introduction
Reduced Indy (I am Not Dead, Yet) gene expression in D. melanogaster and C. elegans 
promotes longevity in a manner akin to caloric restriction in most studies (1–4). Long-lived 
flies with lower Indy expression have decreased whole body fat stores, lower expression of 
insulin-like proteins, and increased mitochondrial number (3, 5). The Indy gene product is a 
cation-independent, electroneutral tricarboxylate carrier (6, 7), able to transport citrate 
across the plasma membrane as its preferred substrate. Indy is highly expressed in organs 
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involved in energy homeostasis in flies (8). In mammals, the gene product of Slc13a5 
(mIndy) encodes the sodium-coupled citrate transporter NaCT (mINDY); it shares the 
highest sequence and functional similarity with D. melanogaster INDY (9) and is highly 
expressed in liver tissue (6, 7, 10–12). In mammals, mINDY mediates an electrogenic 
cotransport of a various di- and tricarboxylates, with the highest affinity for citrate (6). 
Citrate and succinate are mINDY substrates with the highest plasma concentrations (11). 
The amino acid sequence of the N-terminal sodium- and the carboxy-binding pocket are 
highly conserved between many species, from bacteria to mice to human (13).
Recently, our lab translated findings from Drosophila into mammals by showing that mIndy 
deletion (mINDY−/−) mimics important aspects of caloric restriction in mice (7), without 
reducing caloric intake. mINDY−/− mice gain less weight on a high-fat diet and during the 
aging process together with lower liver fat content and reduced insulin resistance (7). 
Furthermore, we showed that liver specific mIndy knockdown using anti-sense 
oligonucleotides (ASOs) in adult rats reduced hepatic lipid storage and enhanced hepatic 
insulin sensitivity upon feeding a HFD (14). Finally, a competitive, stereo sensitive small 
molecule inhibitor of the mINDY transporter offered complete protection from diet-induced 
glucose intolerance in mice and ameliorated diet-induced fatty liver disease as shown by an 
independent research group (15).
The cytokine interleukin-6 (IL-6) is a pleiotropic cytokine with a complex role in 
inflammation and metabolic disease. IL-6 binding to its cell surface receptor with 
subsequent activation of janus family kinases and phosphorylation of signal transducer and 
activator of transcription 3 (STAT3), promoting its nuclear translocation, DNA binding, and 
subsequent target gene expression, including important genes of the acute phase reaction. 
Moreover, PI-3 phosphorylation through IL-6 results in Akt activation. IL-6 also activates 
the pro-oncogenic Ras/Raf/MAPK 1/2 signaling pathway. In obesity and the metabolic 
syndrome, cytokines, such as IL-6, are highly secreted from adipose tissue and have been 
proposed to promote accompanying metabolic diseases, i.e. insulin resistance, type 2 
diabetes and non-alcoholic fatty liver disease (NAFLD) (16–19). However, anti-
inflammatory and beneficial metabolic actions of IL-6 have been reported as well (20–22). 
Thus, the exact role of IL-6 in metabolic regulation remains highly controversial (23).
Given the therapeutic potential of mINDY inhibition in metabolic disease and aging, our aim 
was to investigate the role of the human mIndy homolog in the pathophysiology of obesity 
and NAFLD, and the regulation of its expression under conditions associated with obesity. 
We observed that mIndy expression was increased in obese patients with NAFLD and that 
the cytokine IL-6 is a potent regulator of the human mIndy homolog.
RESULTS
Human mIndy Tissue Distribution
To determine mIndy distribution in human subjects, semi-quantitative PCR measurements of 
mIndy expression were performed in different tissues. mIndy expression was markedly 
higher in liver tissue compared to all other tissues studied (Figure 1A), with skeletal muscle 
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and colon showing minimal mIndy expression levels confirming previous reports in mice 
(7), rats (12, 14) and human subjects (11, 24).
Transport kinetics of human mINDY
Human mIndy (SLC13A5) cDNA was cloned, transfected into HEK293 cells, and the 
uptake capacities of mINDY for citrate and succinate were analyzed. mINDY proved to be a 
high capacity transporter for citrate over a broad range of concentrations (0–5000 μM), 
which encompasses physiological concentrations (25) (Km=2254±207 μM, 
Vmax=25117±1051 [pmol/mg·min−1]) and a succinate transporter with an intermediate 
capacity (Km=5156±665 μM, Vmax=1046±71 [pmol/mg•min−1]) (Figure 1B and 1C).
Human hepatic mINDY mRNA expression is increased in insulin resistant patients with 
obesity and nonalcoholic fatty liver disease
Forty-nine liver samples were collected from patients undergoing hepatic surgery and 
processed for the quantitative determination of mIndy mRNA levels. With respect to current 
diagnostic criteria (26) all subjects presenting with ≥5% steatotic hepatocytes in our 
histopathological analysis were considered as having NAFLD. Accordingly, 37% of our 
study subjects had no sign of any pathological condition in the respective liver tissue, 
compared to 63% suffering from NAFLD. Liver samples were collected before the blood 
supply to the liver was clamped (Pringel maneuver) to minimize cold ischemia. 
Characteristics of patients are given in Table 1. mIndy expression was positively correlated 
to BMI (r=0.361, P=0.011, Figure 2A), waist circumference (r=0.418, P=0.003, Figure 2B), 
body fat (r=0.441, P=0.020, Figure 2C), and nominally for insulin resistance as assessed by 
HOMA-IR (r=0.333, P=0.019), and hepatic insulin resistance index (r=0.316, P=0.027). Of 
note, the strongest correlation was present with histology determined steatosis (r=0.688, 
P<0.001, Figure 2D). To determine whether mIndy expression was independently associated 
with hepatic steatosis, we adjusted for several potential confounders, including age, sex, 
waist circumference and insulin resistance, by means of multivariate linear regression 
analysis. The degree of liver histology-determined steatosis remained significantly 
associated with mIndy expression (Model in Table 1B), suggesting that mIndy 
independently predicts human hepatic steatosis. Total RNA microarrays from liver samples 
of patients with low (1±0.1 AU) and high mINDY expression (3.4±0.4 AU), matched for 
BMI and other metabolic parameters, except for hepatic fat content (34±5% versus 16±2 %, 
for high versus low expressed mIndy, respectively, P=0.02, n=3) revealed biological 
processes involved in hepatic lipid metabolism and the acute phase response being activated 
in patients with high mIndy expression in gene ontology enrichment analysis (Table 2).
High fat, high sucrose diet increases hepatic mIndy expression in non-human primates
To independently confirm our human data, we used a cohort of non-human primates raised 
in a controlled environment. Fourteen middle-aged male rhesus monkeys were randomized 
into two groups and fed either a standard diet (SD, n=4) or a high-fat, high sucrose (HFS) 
diet (n=10) for two years, as described (27). Monkeys fed a HFS diet showed significant 
increases in body weight (Figure 3A), waist circumference (Figure 3B) and serum IL-6 
levels (Figure 3C) when compared to SD-fed animals. Total RNA microarrays from monkey 
liver samples, and pairwise comparison between HFS and SD cohorts indicated a 3.5-fold 
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increase in the z-ratio for mIndy in response to HFS. These data were confirmed by RT-
PCR, with a 3.7±0.7 fold increase in hepatic mIndy expression in obese, HFS-fed monkeys 
as compared to SD-fed controls (Figure 3D). These data show that a high fat high sucrose 
diet or the resulting diet induced obesity increases mIndy expression in non human primates.
Similarly, in non-fasted male 16 week high fat diet fed C57BL/6 mice, hepatic mIndy 
expression was induced 2.5±1.0 fold in comparison to the SD-fed group (SD, n=4–5; 
1.0±0.2) (Figure 3E). Interestingly, in a murine NASH model (high fat/methionine low-
choline deficient diet=HFD-CD), hepatic mIndy expression was markedly increased in 
HFD-CD-fed mice (n=4) with > 20-fold increase (Figure 3F) after 6 weeks of the 
intervention. The increase of mIndy expression in the course of NASH was also time-
dependent (data not shown). Since these data suggest that mIndy is regulated by an 
inflammatory mediator, expression levels of mIndy in murine hepatoctyes and Kupffer cells 
were analysed independently. In Kupffer cells, mIndy expression was very low, on a normal 
diet as well as on a HFD (Figure S1A).
The cytokine interleukin-6 (IL-6) is positively associated with hepatic mIndy expression
Other inflammatory mediators might also induce mIndy. Total RNA microarrays suggested 
that high mIndy expression was associated with activation of some acute phase response 
components (Table 2). The acute phase response, which serves as a core of the innate 
immune system, is initiated and mediated by a number of cytokines, most importantly by 
IL-6 (28). IL-6 independently predicted the degree of hepatic steatosis at a cut off level of 
4.81pg/ml (29, 30). Therefore, patients were grouped according to serum IL-6 levels below 
or above this threshold. In patients with plasma IL-6 levels above this threshold, mIndy 
expression was twofold higher compared to patients with IL-6 levels below this threshold 
(P=0.008) (Figure 4A). In a cross sectional comparative analysis of serum from these 
patients, hepatic mIndy expression positively correlation with circulating IL-6 levels after 
adjustment for liver fat (r2=0.300; P=0.038, data not shown).
IL-6 induces hepatic mIndy expression in primary human hepatocytes and in mice
Treatment of human primary hepatocytes with IL-6 (50ng/ml) induced mIndy expression in 
a time-dependent manner, with a 42 ± 14 fold increase after 24 h of IL-6 (P=0.031) (Figure 
4B). Moreover, blockade of IL-6 signalling with the human monoclonal IL-6 receptor 
antibody tocilizumab completely abolished IL-6′s ability to increase mIndy expression 
(Figure 4C).
To assess the ability of IL-6 to recapitulate this effect in vivo, IL-6 was injected 
intravenously into C57BL/6 wildtype mice. In this setting, hepatic mIndy expression was 
induced by 3.5±0.3 fold after 240 min (Figure 4D). To independently verify the role of the 
cognate IL-6 receptor in the regulation of mIndy expression, liver samples of mice with a 
targeted liver-specific deletion of the IL-6 receptor (IL-6RL-KO) were analyzed, which were 
generated by crossing IL-6R fl/fl mice to ALFP-Cre recombinase mice as described in (21). 
Deleting the hepatic IL-6 receptor led to a marked 68±4% reduction in hepatic mIndy 
expression when compared to IL-6Rfl/fl mice (Figure 4E). Total RNA microarrays from 
these liver samples indicated that ~900 genes where reduced in IL-6RL-KO mice compared to 
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IL-6R fl/fl. mIndy ranked 20th among the top negatively regulated genes. Together, these 
data confirm that IL-6 regulates mIndy transcription in both human and mouse livers via the 
IL-6 receptor.
To determine whether the action of IL-6 can also be attributed to an endocrine-mediated 
mechanism, human non-parenchymal cells, including Kupffer cells, were co-cultivated with 
hepatocytes, and then stimulated with lipopolysaccharide (LPS), which provides a strong 
stimulus for macrophages to secrete an array of pro-inflammatory cytokines, including IL-6. 
In this setting, mIndy expression was induced 5-fold (Figure 4F), and pre-incubation of the 
co-culture with tocilizumab largely reduced the induction of mIndy by LPS stimulated cells. 
When hepatocytes were cultured without non-parenchymal cells, such as Kupffer cells, the 
LPS response was reduced but not completely presvented (Figure S1B). Together, these data 
suggest that IL-6, but not other cytokines, induces mIndy in an inflammatory paracrine and 
endocrine-related setting, because IL-6 receptor blockade largely abolished the response.
Human mINDY is induced via the transcription factor Stat3
5′-RACE experiments were performed to identify the transcription start site of the human 
mIndy (SLC13A5) gene, with gene-specific primers for reverse transcription in exon 6 and 
nested PCR primers located in the fifth and third exons. A possible transcription start site 
located approximately 40 bp upstream of the 5′-end of the published start ATG was found in 
5 out of 7 clones that contained sequences continuing into the first exon (Figure 5A). RT-
PCR was used to verify the putative transcription start site. Genomic DNA and cDNA were 
amplified with specific primers, whereby the forward primers were either located 26 bp 
upstream of the potential transcription start site or at the published ATG start codon. 
Normalized mINDY template numbers did not differ between cDNA and genomic DNA 
when using the primer directed at the ATG start codon, whereas the normalized mIndy 
template number in the cDNA was reduced about 95% versus genomic DNA using the 
primer upstream of the putative transcription start site. Hence, we tentatively assigned the 
5′-upstream region of the latter transcription start site as promoter region. In silico analysis 
of the 618 bp human mIndy promoter fragment revealed a potential Stat responsive element 
sequence as shown by MatInspector software. Moreover, a second Stat responsive element 
was identified with the Stat consensus sequence TT(N4–6)AA (Figure 5A, 5C). Two reporter 
gene constructs were generated by cloning either a stretch of 618 bp containing both Stat 
responsive elements or a fragment of 376 bp length including one Stat binding motif 
upstream of the start ATG of the human mIndy gene, including the putative transcription 
start site, in front of luciferase in the vector pGL3-basic. Transiently transfection of mouse 
hepatocytes with these Stat-containing human mINDY promoter constructs increased the 
luciferase activity about 53 % and 138 %, when either one, or both Stat responsive elements 
were present, respectively (Figure 5B). To determine which of the elements is indispensible 
for the induction of mINDY by IL-6, mutations were introduced into both Stat3-binding 
elements at the 376 bp and 618 bp mIndy promotor fragments by PCR-based site-directed 
mutagenesis (Figure 5C) Surprisingly, none of the mutations in the potential Stat3-binding 
sites reduced mINDY promoter activity when stimulated with IL-6 (Figure 5D). These data 
suggest that other binging sites, an indirect mechanism or non-transcriptional effects 
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contribute to the Stat3-dependent transactivation of the mIndy gene following IL-6 
stimulation.
IL-6 mediated metabolic effects via mINDY
mINDY is a transporter of citrate from the interstitial space into the cytosol. Incubation of 
primary human hepatocytes with IL-6 (50ng/ml) in the presence of physiological 
concentrations of citrate (10μmol/l) led to a significant increase both in 14C- citrate uptake 
(Figure 6A) and lipogenesis from citrate (Figure 6B). Deletion of mIndy in primary 
hepatocytes isolated from mINDY−/− mice (7) completely prevented these effects of IL-6 
(Figure 6C and 6D). To determine whether this also has a role in the in vivo setting, we 
generated hepatocyte specific mINDY KO mice as described in the methods section. In these 
mice, mINDY expression was completely abolished in the liver, but not other tissues such as 
adipose tissue, muscle and brain (data not shown) compared to mINDY fl/fl mice. IL-6 was 
infused for 14 days using mini osmotic pumps as described in (31) into mINDY-L-KO and 
mINDY fl/fl. mINDY fl/fl mice without IL-6 infusion were used as negative control. One 
week prior to the experiment, an intravenous line was inserted into the right jugular vein. On 
the day of the experiment, mice were fasted overnight and infused with 7μCi 14C-Citrate 
continuously and livers were taken after 4 hours of infusion. Fatty acid synthesis from citrate 
was determined. Our data show that chronic infusion of IL-6 for 14 days nearly doubled 
fatty acid synthesis from citrate in livers of mINDY fl/fl mice. Liver specific deletion of 
mIndy completely prevented IL-6 induced fatty acid synthesis from citrate. These data 
suggest that mINDY mediates IL-6 induced hepatic lipid synthesis from citrate in mice in 
vivo (Figure 6E). In line with these findings, HEK293 cell lines with stable 50 fold 
overexpression of mIndy lead to a concentration dependent uptake of citrate (Figure 1B). 
Citrate induced lipogenesis increased by more than 130 fold in these cells (Figure S2). 
Taken together, these results suggest a novel function of IL-6, namely to stimulate 
hepatocyte citrate uptake and hepatic citrate induced lipogenesis in vivo. The effect of IL-6 
is mediated via mINDY.
Significance of human mINDY compared to mouse and rat mINDY
Finally, a recent publication raised questions about the translatability of mINDY as a target 
for the treatment of metabolic disease from the mouse to the human situation due to 
differences in uptake properties between species (32). Therefore, we directly measured 14C-
citrate uptake into mouse, rat, and human primary hepatocytes incubated with low 
physiological concentrations of citrate. In this setting, citrate uptake was highest in human 
primary hepatocytes, followed by mouse and rats (Figure 6F). These data directly show that 
human mINDY takes up citrate even in low physiological doses and are rather supportive for 
the notion that human mINDY is a viable target for the treatment of metabolic disease.
DISCUSSION
Reduced Indy gene expression increases life span in lower organisms in most (1, 3, 7, 33) 
but not in all (34) studies. Moreover, deletion or knock down of Indy or its homologs lead to 
a lean phenotype by mechanisms akin to caloric restriction, without a reduction in food 
intake (1, 3, 7, 33). Here, we provide new data showing similar associations in humans. In 
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lean subjects with low amounts of liver fat, mIndy expression was low, and mIndy 
expression increased with increasing BMI and liver fat content. Furthermore, our data from 
non-human primates indicate that mIndy is regulated in response to a ‘unhealthy’ high fat, 
high sucrose diet. In mice, a high fat diet but to a larger extend a high fat- NASH inducing 
diet (methionine low, choline deficient), also induced mIndy in the liver. Taken together, 
these data show for the first time that mIndy is regulated by the nutritional state and might 
therefore play a pathophysiological role in diet induced obesity and associated conditions, 
such as NAFLD.
Our data suggest that the association between mINDY, obesity and NAFLD was mediated, 
at least in part, by the cytokine IL-6. Moreover, we provide evidence for human mIndy being 
a target gene of Stat3 in response to IL-6. Both, the treatment of primary human hepatocytes 
with IL-6 and intravenous administration of IL-6 in mice markedly increased hepatic mIndy 
mRNA levels. This gene encodes the plasma membrane citrate transporter mINDY (NaCT, 
SLC13A5) and, thus, stimulation of human and rodent hepatocytes with IL-6 enhanced 
cellular uptake of citrate. Citrate, in turn, is a precursor of acetyl-CoA and fatty acid in the 
liver. mIndy induction in mice in vivo and in murine and human primary hepatocytes in vitro 
required the cognate IL-6 receptor. Indeed, the monoclonal human IL-6R antibody 
tocilizumab abolished the effect of IL-6 on mIndy expression and IL-6RL-KO mice displayed 
significantly lower hepatic mIndy levels. Our data show that two Stat responsive elements by 
in silico analysis of the human mIndy promoter 5′ upstream of the putative transcription 
start site, consistent with the notion that Stat3 transcriptional activity induces the human 
mIndy promoter. Indeed, reporter gene constructs containing the two Stat binding sites were 
activated by IL-6. However, mutating these Stat-binding sites did not result in reduced 
mIndy promoter activity. These data suggest that either i) other enhancer-elements, far more 
upstream of the transcription site mediate the effect, ii) the induction is mediated indirectly 
via Stat3-dependent induction of other transcription factors, iii) mIndy mRNA is regulated at 
the posttranscriptional level. More studies are needed to clarify these possibilities.
After stimulation of human non-parenchymal cells, including Kupffer cells, with LPS, 
inducing an array of cytokines, IL-6 receptor blockade attenuated mIndy induction in 
hepatocytes. When only hepatocytes were cultured, the LPS response was reduced. These 
data suggests that IL-6 likely is a cytokine contributing to the induction of mIndy in a pro-
inflammatory setting and that the effect is mediated in both, a paracrine and endocrine 
manner from immune competent cells. Collectively, these data provide evidence for IL-6 to 
induce the human longevity gene homolog mIndy via Stat3 in human and rodent liver 
tissues.
IL-6 is increased in obesity, T2D and NAFLD. Obesity and NAFLD are characterized by a 
chronic inflammatory state (35). The nature of the immune response is unique as compared 
to an acute inflammatory responses and has a well characterized impact on metabolic 
regulation (35). In obesity, accumulation of immune cells such as macrophages and T-
lymphocytes in the liver and white adipose tissue leads to increased secretion of IL-6 (35). 
The effect of IL-6 on hepatic lipid metabolism has been investigated with diverging results 
(20–22, 31, 36–40). IL-6 transgenic animals were protected from HFD induced obesity and 
fatty liver. IL-6 levels in these animals are, however, several fold higher than IL-6 
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concentrations in obesity (39). In studies in IL-6-deficient, and IL-6R deficient mice, the 
course of diet-induced hepatic steatosis support a protective effect of the cytokine in obesity 
and fatty liver disease (41, 42). In these animals, a compensatory increase in many other 
cytokines has been reported (21). In contrast, low dose application of murine IL-6 in mice 
lead to hepatic steatosis (43). Subchronic IL-6 administration in IL-6-deficient mice 
exacerbated hepatic steatosis by increasing lipogenesis (44). Importantly, neutralization of 
IL-6 with neutralizing antibodies in HFD fed mice improved glucose tolerance, ameliorated 
liver fat content (45). Longterm IL-6 incubation of rat hepatocytes increased lipid synthesis 
(Brass and Vetter et al., 1994), i.p. IL-6 administration in mice stimulated hepatic 
lipogenesis by increasing hepatic citrate (46) and acetyl-CoA concentrations (19). Taken 
together, these data show that IL-6 is a pleiotropic cytokine with complex roles in metabolic 
disease. Our data from patients and non-human primates confirm the association between 
IL-6 and anthropometric measures of obesity and hepatic lipid content. Moreover, our data 
show an association between mIndy expression and IL-6 as well as obesity and NAFLD. 
Our in vitro studies corroborate the observation by showing that IL-6 induced mIndy 
expression in primary hepatocytes from human and mice, and that IL-6 increased hepatic 
citrate uptake and hepatic lipogenesis from circulating citrate via mINDY in vivo.
Circulating citrate concentrations range from 50–150 μmol/L. We provide evidence that 
human mINDY is a high capacity transporter for circulating citrate, which is hardly 
saturated by circulating concentrations. Thus, mINDY allows a continuous uptake of citrate 
into hepatocytes. Citrate is a central metabolite, both, in cytosolic and in mitochondrial 
metabolism, by connecting carbohydrate catabolism and lipogenesis. Citrate is the main 
carbon source of fatty acid synthesis which has recently been shown to be enhanced by IL-6 
(19). Moreover, citrate acts as an allosteric activator of acetyl-CoA carboxylase (ACC). 
Cytosolic citrate also contributes to NADPH generation via malic enzyme for lipogenesis 
(47). In line with this mechanism, siRNA mediated mIndy knockdown reduced total fat 
content in human hepatocytes (24). Knockdown of mIndy in rats using ASOs (14)and in 
mice using siRNA (48) reduced liver fat content when rats were fed a HFD. Most 
importantly, inhibition of mINDY using a novel small molecule improved glucose tolerance 
and ameliorated liver fat content upon high fat feeding in mice (15). Conversely, our data 
show that overexpression of mINDY in HEK293 cells resulted in an increase in citrate 
uptake and intracellular fatty acid and sterol synthesis. Moreover, enhancing the activity of 
citrate transport by mINDY in HepG2 cells augments citrate-induced lipid synthesis (12, 
49). Inducing mIndy in obesity and NAFLD, might, thus, contribute to the pathogenic 
process by enhancing the uptake of citrate which is then used to fuel hepatic lipid synthesis.
In summary, our data show that the longevity gene homolog mIndy was regulated in humans 
according to the nutritional state and that IL-6 increased human hepatocyte mIndy 
expression in a paracrine and endocrine manner. Our work describes a promoter sequence of 
human mIndy that is located upstream of the most frequent transcription start site, which 
was determined by 5′-RACE. We also describe a novel function of IL-6, namely the 
induction of citrate uptake into human primary hepatocytes via mINDY and by this 
mechanism, an induction of lipid synthesis in human primary hepatocytes. Based on our data 
in humans, future studies are needed to address the important question whether or not the 
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inhibition of human mINDY is beneficial in the treatment of metabolic disease, such as 
obesity, NAFLD and type 2 diabetes.
EXPERIMENTAL PROCEDURES
Patients
mINDY gene expression in different tissues was measured in the Human Total RNA Panel 
(BD Biosciences Clontech, Heidelberg, Germany), supplemented with RNA from human 
liver from our laboratory. For liver samples and hepatocytes, experimental procedures were 
performed according to the guidelines of the charitable state-controlled foundation Human 
Tissue and Cell Research, with the informed patient’s consent approved by the local Ethical 
Committee of the Charité University School of Medicine Berlin (EA2/135/08). All subjects 
gave written informed consent at least 24 hours prior to surgery. Forty-nine patients were 
enrolled between February 2009 and March 2010. Details regarding inclusion and exclusion 
criteria have been published (50), German Clinical Trials Register: DRKS00005450.
Preparation and cultivation of primary human hepatocytes
Tissue samples from liver resections were obtained from patients undergoing partial 
hepatectomy. The experimental procedures were performed according to the guidelines of 
the charitable state-controlled foundation Human Tissue and Cell Research, with the 
informed patient’s consent approved by the local Ethical Committee of the Charité 
University School of Medicine Berlin (EA2/007/13). Detailed information is given in the 
Supplemental Section.
Animals
Non-human primates—Studies were performed as described (27). Detailed information 
is given in the Supplemental Section.
Mice—Generation of mINDY-KO mice and IL-6RαL-KO mice have been described 
previously (7, 21). Detailed information is given in the Supplemental Section.
Generation of liver specific mIndy KO mice: We previously generated a targeting vector, in 
which exons 1 to 6 of the SLC13A5 gene were flanked by loxP sites (7). After yielding 
SLC13A5 (mIndy) fl/fl, these mice were crossed with Albumin-Cre mice {Kellendonk 
2000}, and heterozygous animals were further intercrossed to mIndyFL/FL Alb-Cre, i.e., 
hepatocyte-specific mIndy knockout mice on a C57/BL6 background (mIndy L-KO).
Male C57BL/6J mice were purchased from Charles River Laboratories. First mice cohort 
were fed with a high fat diet or with a normal chow dor 16 weeks, starting at the age of 4 
weeks. Second mice cohort were fed with a high fat-low methionine-choline deficient diet 
(A06071302 from Research Diets, Brunswick, NJ), used for NASH development, or with a 
normal fat control diet (A08051501 from Research Diets) for six weeks. Upon completion 
of the feeding period, a systemic perfusion of the mice with PBS was performed and livers 
were excised.
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Chronic IL-6 treatments: Alzet osmotic pumps (Durect, Cupertino, CA) were used in mIndy 
L-KO and mINDy fl/fl littermate control mice. IL-6 was infused for 14 days with an 
infusion rate of 1 μl/h (32 μg/ml hIL-6 in 0.9% NaCl, 0.1% BSA). One week prior to the 
experiment, an intravenous line was inserted into the right jugular vein. On the day of the 
experiment, mice were fasted overnight and infused with 7μCi 14C-Citrate continuously. 
After 4 hours, mice were sacrificed and livers were taken and snap frozen within 1 minute 
and stored at −80°C for later analysis. Fatty acid synthesis from citrate was determined in 
these livers as described in (7).
Hepatocyte preparation and cultivation—Density gradient-purified hepatocytes were 
prepared without the use of collagenase, as described previously (12). Detailed information 
is given in the Supplemental Section.
Microarray analysis—Microarray data was analyzed using DIANE 6.0, a spreadsheet-
based microarray analysis program based on JMP 7.0 from SAS system, as mentioned in our 
previous studies (7).
Identification of transcription initiation sites by 5′-RACE—Total RNA from two 
different primary human hepatocyte cultures was used with 5′-RACE system 2.0 (Life 
Technologies, Eggenstein, Germany) as described previously (12).
Generation of human mINDY promoter constructs—Fragments containing 618 bp 
or 376 bp of the putative human mIndy promoter were generated from human genomic DNA 
by PCR using specific primers. Fragments were cloned in the forward orientation into 
pGL3-basic (Promega, Mannheim, Germany). Luciferase-based reporter assays with 
transfected primary mouse hepatocytes were performed as described previously and 
compared against empty vector control transfected hepatocytes (12). Primer oligonucleotides 
and plasmids are given in the supplemental methods section.
Statistical Analysis
Detailed information is given in the Supplemental Section.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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mINDY mammalian homolog of Indy (protein, NaCT)
IL-6 Interleukin-6
STAT-3 signal transducer and activator of transcription 3
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HFD high fat diet
PI-3 phosphoinositol 3
MAPK mitogen-activated protein kinases
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PCR polymerase chain reaction
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Figure 1. Human mIndy tissue distribution and functional characteristics
A) Human mIndy mRNA tissue expression in different tissues. B and C) mINDY transport 
kinetics for citrate (B) and succinate (C) were carried out in HEK293 cells transfected with 
either the pIndy-human.31 plasmid or empty expression vector pcDNA3.1(+). The net 
uptake is expressed as the difference between the uptake of substrates into HEK293 cells 
overexpressing human mINDY and pcDNA-transfected controls (n=3–6 for each 
concentration). Km values were determined by fitting the data to a non-linear regression 
curve fit.
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Figure 2. mIndy expression in the liver of patients with different BMI and liver fat contents
A) mIndy expression was positively associated with BMI, B) waist circumference, C) body 
fat, D) histologically assessed liver fat content. The degree of liver histology-determined 
steatosis remained significantly associated with mIndy expression after adjustment for 
several confounders (Model in Table 1), identifying mIndy as an independent risk factor for 
NAFLD in our cohort of patients.
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Figure 3. mIndy expression in liver tissue from non-human primates
Rhesus monkeys were maintained on a standard diet (SD, n=4) or a high fat, high sucrose 
diet (HFS, n=10) for 24 months. Monkeys on HFS diet had A) increased BMI, B) larger 
waist circumference, C) elevated serum IL-6 levels, and D) increased hepatic mIndy 
expression compared to SD-fed animals. E) In non fasted male 16 week high fat diet fed 
C57BL/6 mice, hepatic mIndy expression was induced compared to the SD-fed group (n=4–
5) F). In a murine NASH model (high fat/methionine low-choline deficient diet=HFD-CD), 
hepatic mIndy expression was markedly increased after 6 weeks of the intervention.
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Figure 4. mIndy interacts with IL-6
A) IL-6 is a predictor of hepatic steatosis at cut-off level 4.81pg/ml (29, 30). Patients were 
divided into two groups with IL-6 levels below or above this threshold and mIndy expression 
in liver samples were determined. B) In human primary hepatocytes, IL-6 induced mIndy 
expression in a time-dependent manner (n=6). C) Blockade of the IL-6R with the 
monoclonal IL-6R antibody tocilizumab, completely abolished IL-6-mediated induction of 
mIndy (n=6). D) I.v. injection of IL-6 into C57BL/6 wildtype mice leads to an increase in 
mIndy mRNA levels (n=4). E) Targeted, liver-specific deletion of the IL-6R (IL-6RL-KO) 
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(n=3) in mice leads to a decrease in hepatic mIndy expression. F) Human non-parenchymal 
cells (including Kupffer cells) were co-cultivated with human primary hepatocytes and 
stimulated with lipopolysaccharide (LPS) with or without tocilizumab (n=3).
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Figure 5. Characterization of the human mIndy promoter
The putative start site and upstream promoter region of the human mIndy gene were 
determined by 5′ RACE (A) The most frequent transcription start site (bold) was located 40 
bp upstream of the ATG start codon. (B) Reporter gene constructs were generated by cloning 
the 621 bp (prom-621, blue top) or 379 bp (prom-379, red top) sequence upstream of the 
ATG start codon of human mIndy in front of a luciferase reporter. C) Site directed 
mutagenesis strategy in 376 bp and 618 bp mIndy promoter fragments. D) Site directed 
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mutagenesis at STAT3-elements 376 bp and 618 bp in the mIndy promoter did not reduce 
promoter activity. Luciferase activity was determined and compared to empty vector control.
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Figure 6. Cytoplasmic citrate uptake and lipid synthesis
A,B) In human primary hepatocytes, IL-6 increased cytoplasmic influx of citrate (A) and 
lipid synthesis from citrate (B). C and D) IL-6 increased citrate uptake (C) and lipid 
synthesis from citrate (D) in a primary culture of hepatocytes from wildtype (WT) mice, but 
not from mice with deletion of mIndy (mINDY-KO). E) In liver specific mINDY KO mice 
(mINDY-KO) and mINDY fl/fl control mice, IL-6 was infused for 14 days via miniosmotic 
pumps. 14C-citrate was then administered iv for 4 hours and fatty acid synthesis was 
determined in liver of these mice. mINDY fl/fl mice without IL-6 infusion were used as 
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negative controls. IL-6 increased fatty acid synthesis from citrate, an effect prevented when 
mIndy was deleted in the liver. F) 14C Citrate uptake into primary mouse, rat and human 
hepatocytes incubated for 24h hours with citrate. Data represent values+/- SEM from 
primary hepatocytes from independent assays from three different mice, 5 different rats and 
5 different human donors.
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Table 1
Human patient characteristics and model calculation
n (male) 49 (23)
age (years) 59±2
BMI (kg/m2) 26.7±0.9
body fat (%) 32.9±1.4
waist circumference (cm) 96.1±2.3a
SBP (mm Hg) 133±3





steatosis score (0–3) 0.92±0.13a
ethanol intake (drinks/week) 1.4±0.3
Model
Dependent variable: Hepatic steatosis
Independent variable
Beta coefficient (P-value)







Hepatic mINDY expression 0.442 (0.008)
Significant correlations are shown in bold.
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Table 2
Gene Ontology enrichment analysis in livers from subjects with high vs low mINDY expression.
Gene Ontology Term Zscore (P_value) (fdr)
GO0042627 CHYLOMICRON 10.084 0.000 0.007
GO0042157 LIPOPROTEIN METABOLIC PROCESS 9.829 0.000 0.006
GO0046870 CADMIUM ION BINDING 9.253 3.18E‐11 3.37E‐09
GO0005319 LIPID TRANSPORTER ACTIVITY 8.126 0.002 0.034
GO0006953 ACUTE PHASE RESPONSE 6.519 0.003 0.042
GO0006572 TYROSINE CATABOLIC PROCESS 5.016 0.002 0.036
GO0004984 OLFACTORY RECEPTOR ACTIVITY 4.036 9.82E‐19 2.38E‐16
GO0005840 RIBOSOME 3.848 0.001 0.014
GO0003735 STRUCTURAL CONSTITUENT OF RIBOSOME 3.684 0.001 0.021
GO0008270 ZINC ION BINDING −8.407 3.40E‐13 4.44E‐11
GO0003677 DNA BINDING −8.592 9.26E‐13 1.12E‐10
GO0006350 TRANSCRIPTION −9.520 4.12E‐15 6.35E‐13
GO0046872 METAL ION BINDING −9.790 8.75E‐16 1.41E‐13
GO0016020 MEMBRANE −9.979 4.72E‐17 8.89E‐15
GO0006355 REGULATION OF TRANSCRIPTION DNA DEPENDE −10.015 7.29E‐17 1.30E‐14
GO0005737 CYTOPLASM −11.918 6.03E‐21 1.86E‐18
GO0005515 PROTEIN BINDING −14.315 4.65E‐29 1.97E‐26
GO0005634 NUCLEUS −14.608 1.50E‐33 1.02E‐30
Gene Ontology terms of biological processes. Positive z-score indicates increased in patients with high mIndy expression. Negative z-score 
indicates reduced in patients with high mIndy expression.
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